MedTrace Logo

Study Evaluating Safety Of Patients Switching To ReFacto AF In Usual Care Settings

NCT00884390 · Status: TERMINATED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 208

Last updated 2014-09-01

Study results available
· View outcomes & findings →

Summary

The study will be investigating safety in patients who switch to ReFacto AF from ReFacto and other Factor VIII products.

Conditions

Interventions

DRUG

moroctocog alfa (AF-CC) (ReFacto AF)

Providing moroctocog alfa (AF-CC) as test article for use during this study.

PROCEDURE

Laboratory tests

Laboratory samples are collected during study visits, in order to collect safety and efficacy data related to the administration of test article.

Sponsors & Collaborators

Principal Investigators

  • Pfizer CT.gov Call Center · Pfizer

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
12 Years
Sex
MALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2009-05-31
Primary Completion
2013-03-31
Completion
2013-03-31

Countries

  • Austria
  • Belgium
  • Denmark
  • Finland
  • France
  • Germany
  • Greece
  • Hungary
  • Italy
  • Netherlands
  • Romania
  • Spain
  • Sweden
  • United Kingdom

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00884390 on ClinicalTrials.gov